Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.
SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials. The publication demonstrated that SOR-C13 was safe and well tolerated, without evidence of the significant toxicities often observed with cytotoxic chemotherapy.
In addition, the study provided preliminary indication of anticancer activity, including promising activity in two patients with pancreatic cancer, who had failed three prior regimens of treatment.
SOR-C13 has been granted orphan drug designation for the treatment of both ovarian and pancreatic cancer by the FDA.
“Anonymous peer review helps validate our methods, our data interpretation and our conclusions from this important study,” Prof. Jack Stewart, CSO, said in a statement. “These results, plus our two orphan drug status designations, warrant developing this new drug to the next human trials,” he added.
The open-access publication can be viewed online here.
